Soliris REMS Should Be Modified, Not Eliminated, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Alexion’s risk management program could benefit from easing current requirement for MedGuide distribution with every infusion and streamlining surveys of prescribers’ knowledge about meningococcal risks.
You may also be interested in...
Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes
FDA advisory committee will weigh potential tweaks to orphan drug’s risk management plan, which is meeting informational goals regarding meningococcal infections but could be burdening prescribers with repeated assessments.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.